inositol has been researched along with Dementia, Vascular in 9 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Dementia, Vascular: An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been investigated using MRS." | 2.42 | 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. ( Jones, RS; Waldman, AD, 2004) |
| "Furthermore, patients suffering from vascular dementia (VD) had remarkably enhanced TMA/tCr ratios, potentially due to ongoing degradation of myelin." | 1.32 | Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. ( Dierks, T; Frölich, L; Gorriz, C; Herminghaus, S; Lanfermann, H; Maurer, K; Pilatus, U; Wittsack, HJ; Zanella, FE, 2003) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, F | 1 |
| Li, MX | 1 |
| Wang, Y | 1 |
| Tang, W | 1 |
| Watanabe, T | 2 |
| Shiino, A | 2 |
| Akiguchi, I | 2 |
| Shirakashi, Y | 1 |
| Kotani, E | 1 |
| Yoshimura, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Waldman, AD | 2 |
| Rai, GS | 1 |
| Herminghaus, S | 1 |
| Frölich, L | 1 |
| Gorriz, C | 1 |
| Pilatus, U | 1 |
| Dierks, T | 1 |
| Wittsack, HJ | 1 |
| Lanfermann, H | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Marszał, E | 1 |
| Jamroz, E | 1 |
| Paprocka, J | 1 |
| Kluczewska, E | 1 |
| Sokół, M | 1 |
| Jones, RS | 1 |
| Kantarci, K | 1 |
| Petersen, RC | 1 |
| Boeve, BF | 1 |
| Knopman, DS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 1 |
| Weigand, SD | 1 |
| Edland, SD | 1 |
| Smith, GE | 1 |
| Ivnik, RJ | 1 |
| Ferman, TJ | 1 |
| Tangalos, EG | 1 |
| Jack, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
1 review available for inositol and Dementia, Vascular
| Article | Year |
|---|---|
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Dementia, Vascular; Glutamic Acid; | 2004 |
2 trials available for inositol and Dementia, Vascular
| Article | Year |
|---|---|
Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differenti | 2008 |
The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Brain Ischemia; Dementia, Vascular; Female; | 2012 |
6 other studies available for inositol and Dementia, Vascular
| Article | Year |
|---|---|
[Effect of moxibustion on inositol requiring enzyme 1 / X-box binding protein 1 pathway in hippocampal CA1 region of rats with vascular dementia].
Topics: Animals; bcl-2-Associated X Protein; CA1 Region, Hippocampal; Dementia, Vascular; Inositol; Male; Mo | 2023 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Dementia, Vascular; Energy Metabolism; Female; Glutamic Aci | 2003 |
Leukoencephalopathy with macrocephaly and mild clinical course.
Topics: Abnormalities, Multiple; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creatinine; Dementi | 2004 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |